Hussman Strategic Advisors Inc. acquired a new stake in AdaptHealth Corp. (NASDAQ:AHCO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 105,000 shares of the company's stock, valued at approximately $1,000,000. Hussman Strategic Advisors Inc. owned 0.08% of AdaptHealth at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Pacer Advisors Inc. bought a new position in shares of AdaptHealth in the 4th quarter valued at about $76,271,000. FMR LLC grew its position in shares of AdaptHealth by 9.3% in the 3rd quarter. FMR LLC now owns 7,350,549 shares of the company's stock valued at $82,547,000 after acquiring an additional 624,645 shares during the period. Reinhart Partners LLC. lifted its stake in shares of AdaptHealth by 1.1% during the 4th quarter. Reinhart Partners LLC. now owns 6,266,854 shares of the company's stock worth $59,660,000 after buying an additional 68,212 shares during the last quarter. State Street Corp lifted its stake in shares of AdaptHealth by 19.8% during the 3rd quarter. State Street Corp now owns 4,124,284 shares of the company's stock worth $46,316,000 after buying an additional 681,816 shares during the last quarter. Finally, Segall Bryant & Hamill LLC lifted its stake in shares of AdaptHealth by 15.5% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 3,701,808 shares of the company's stock worth $41,571,000 after buying an additional 496,453 shares during the last quarter. Institutional investors own 82.67% of the company's stock.
AdaptHealth stock traded down $0.29 during midday trading on Friday, hitting $8.48. The company's stock had a trading volume of 1,363,088 shares, compared to its average volume of 933,079. AdaptHealth Corp. has a 1-year low of $7.16 and a 1-year high of $11.90. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.24 and a quick ratio of 1.00. The company has a 50-day moving average price of $9.85 and a two-hundred day moving average price of $10.18. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -5.14, a PEG ratio of 1.12 and a beta of 1.12.
A number of analysts have recently issued reports on the stock. UBS Group cut their target price on shares of AdaptHealth from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Canaccord Genuity Group cut their target price on shares of AdaptHealth from $14.00 to $13.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Truist Financial cut their target price on shares of AdaptHealth from $13.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Royal Bank of Canada cut their target price on shares of AdaptHealth from $13.00 to $11.00 and set an "outperform" rating for the company in a research note on Tuesday, November 19th. Finally, Robert W. Baird cut their target price on shares of AdaptHealth from $16.00 to $14.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, AdaptHealth currently has a consensus rating of "Buy" and a consensus target price of $12.20.
Read Our Latest Research Report on AdaptHealth
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.
Before you consider AdaptHealth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AdaptHealth wasn't on the list.
While AdaptHealth currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.